Evidence map›Paper›PMID 8701986›Full record

ArticleThe American journal of pathology1996

CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.

H J Gruss, A Pinto, A Gloghini, E Wehnes, B Wright, N Boiani, D Aldinucci, V Gattei, V Zagonel, C A Smith and 5 more

Abstract read
In one paragraph

Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 76 citations in OpenAlex.

  1. Pathobiological link between CD30 and abnormal lymphocytes in adult T-cell leukemia/lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Transformation of follicular lymphoma to Epstein-Barr virus-related Hodgkin-like lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Hodgkin's lymphoma and CD30 signal transduction.International journal of hematology · 2003
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

H J GrussDepartment of Medical Oncology and Applied Molecular Biology, Robert-Rössle Cancer Center, Humboldt University Berlin, Germany.
A Pinto
A Gloghini
E Wehnes
B Wright
N Boiani
D Aldinucci
V Gattei
V Zagonel
C A Smith
M E Kadin
C von Schilling
R G Goodwin
F Herrmann
A Carbone
Amgen (United States) · USCentro di Riferimento Oncologico · ITMax Delbrück Center · DEFondazione IRCCS Istituto Nazionale dei Tumori · ITHarvard University Press · USIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITIstituto Oncologico Veneto · ITUniversität Ulm · DE

Funding

CUTANEOUS MODEL OF LYMPHOMAGENESISR01CA054062 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KADIN, MARSHALL E. · 1992 to 1994
–
NCI NIH HHS CA 54062-04
6 · The paper itself

Abstract

The CD30 ligand (CD30L) is a type II transmembrane glycoprotein of the tumor necrosis factor ligand superfamily. Recent cloning of CD30L has enabled studies to explore its function and tissue distribution. For instance, recombinant CD30L has been shown to co-stimulate T cells and to act as mitogen for Hodgkin's disease (HD)-derived cell lines. The counter-receptor for CD30L, ie, CD30, is a type I cytokine receptor that is highly expressed by activated T cells, Hodgkin and Reed-Sternberg (H-RS) cells, and anaplastic large cell lymphoma cells. In the present study, recombinant membrane-bound and soluble human CD30L were instrumental to raise a monoclonal antibody (M80) recognizing membrane-bound CD30L on transfected and native cells. With this reagent, a panel of cultured lymphoma-derived cell lines as well as primary normal, reactive, and HD-involved lymphoid tissues were examined for expression of CD30L by immunostaining and flow cytometry. In reactive lymphnodes and tonsils, CD30L was expressed by a small subset of lymphoid cells, histiocytes, and granulocytes. Higher levels of CD30L expression were noted in HD lesions among bystander cells; ie, T cells and granulocytes that surrounded H-RS cells. Native CD30L displayed at the cell surface was functionally active as shown by the ability of fixed granulocytes to interact with CD30+ cell lines. Moreover, CD30L was detectable, although to a lower staining intensity, in primary H-RS cells of all HD tissues investigated regardless of the histological subtype and the phenotype of H-RS cells (ie, CD30+/CD40+ versus CD30-/CD40+). Co-expression of CD30 and CD30L that was seen on H-RS cells of all, except the CD30- nodular lymphocyte predominant, subtypes of HD may point to the use of this pair of molecules in paracrine and/or autocrine mitogenic cell interactions. Monoclonal antibody M80 may thus represent a useful tool for studying CD30L expression on cultured cell lines and primary cells from normal, reactive, and malignant tissues.

Indexed as

Antibodies, MonoclonalAntigens, CDAntigens, SurfaceCD30 LigandCell CountFlow CytometryGranulocytesHodgkin DiseaseHumansImmunohistochemistryLymphoid TissueMembrane GlycoproteinsRecombinant ProteinsReed-Sternberg CellsAntibodies, MonoclonalAntigens, CDAntigens, SurfaceCD30 LigandMembrane GlycoproteinsRecombinant ProteinsTNFSF8 protein, human

Identifiers

PMID8701986
PMCPMC1865328
OpenAlexW1728226545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.